Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staccato Alprazolam PK in Smokers vs Non-Smokers
NCT03516305Phase 1Completed
- Sponsor
- Engage Therapeutics
- Start
- Apr 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alprazolam in epilepsy, sponsored by Engage Therapeutics. Primary endpoints: Maximum observed drug concentration at 36 hours and Area under the concentration versus time curve from zero to infinity at 36 hours. Started Apr 2018; status: completed.
02
Drugs
alprazolam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03516305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516305.